Eversept Partners LP Has $5.10 Million Stock Position in Danaher Co. (NYSE:DHR)

Eversept Partners LP lowered its position in Danaher Co. (NYSE:DHR - Free Report) by 42.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,209 shares of the conglomerate's stock after selling 16,220 shares during the period. Eversept Partners LP's holdings in Danaher were worth $5,098,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Howard Capital Management Group LLC grew its stake in shares of Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate's stock valued at $342,000 after purchasing an additional 48 shares during the last quarter. Tudor Financial Inc. acquired a new position in Danaher during the 3rd quarter worth $414,000. Anchor Investment Management LLC boosted its position in Danaher by 1.3% in the 3rd quarter. Anchor Investment Management LLC now owns 6,039 shares of the conglomerate's stock valued at $1,679,000 after buying an additional 78 shares during the last quarter. World Investment Advisors LLC raised its position in shares of Danaher by 5.3% during the third quarter. World Investment Advisors LLC now owns 12,948 shares of the conglomerate's stock worth $3,600,000 after acquiring an additional 648 shares during the last quarter. Finally, Arvest Bank Trust Division bought a new stake in shares of Danaher during the third quarter worth $254,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 0.4 %

DHR traded up $0.87 during trading on Friday, reaching $197.37. The company had a trading volume of 2,608,666 shares, compared to its average volume of 3,354,979. The company has a market cap of $141.06 billion, a P/E ratio of 37.38, a PEG ratio of 2.66 and a beta of 0.86. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business's fifty day moving average price is $200.87 and its 200 day moving average price is $223.98.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. Equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 25th. Investors of record on Friday, March 28th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, March 28th. This is an increase from Danaher's previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company's stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 11.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DHR shares. UBS Group lowered their price objective on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research report on Wednesday. Jefferies Financial Group dropped their price target on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research note on Tuesday, April 22nd. Raymond James reaffirmed a "market perform" rating on shares of Danaher in a research note on Monday, February 3rd. JPMorgan Chase & Co. dropped their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Tuesday, April 22nd. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $264.40.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.